FMC shares drop almost 7% after rimisoxafen submission and ongoing technical weakness
FMC Corporation (FMC) dropped 6.89% after persistent selling followed the company's regulatory submission for rimisoxafen, a new herbicide, in Brazil. The downtrend is reinforced by FMC trading well below its 20-day, 50-day, and 200-day moving averages, reflecting broad technical weakness that supports the downward move.
Highlights
- FMC Corporation submitted regulatory documents to Brazilian authorities for rimisoxafen, a new herbicide for resistant broadleaf weeds.
- FMC continues to expand its product pipeline, following a recent regulatory submission with the U.S. Environmental Protection Agency.
- Shares of FMC closed at $8.31, firmly below short-, medium-, and long-term moving averages, with technical indicators projecting a trading range of $7.54 to $8.72 over the next five days and a very high probability of further decline.
Rimisoxafen dossier drives pipeline focus amid persistent market outflows
FMC Corporation submitted its regulatory dossier for rimisoxafen, a novel herbicide targeting resistant broadleaf weeds, to Brazilian authorities. This follows a previous submission with the U.S. Environmental Protection Agency, and highlights the company's pipeline expansion. These product development milestones were reported, though price action has remained under broader selling pressure.
Entrenched bearish setup as broad moving average breaches persist
FMC is currently trading below its 20-day, 50-day, and 200-day moving averages ($9.74, $10.6, and $13.12, respectively), signaling entrenched selling and confirming bearish trends across all timeframes. Key support is established at the recent low of $8.22, while resistance is capped at $8.44, with further trend confirmation shown by the bearish 50-day/200-day alignment and the Ichimoku Kijun resistance at $10.89. Momentum readings reinforce this negative setup: the MACD issues a sell signal, momentum is negative, and the ADX at 19.2 reflects a weak and neutral trend. RSI hovers near oversold at 35.94 with a sell outlook, CCI persists in negative territory at -72.1, and BBP at -0.18 confirms intraday seller dominance. The Stochastic RSI and Awesome Oscillator both read neutral, reflecting some short-term indecision even as downside pressure persists. Intraday volatility stands at 8.27%.
Earlier, analysts noted that FMC's exit from the Indian market and ongoing restructuring continued to reinforce a bearish technical outlook. This latest move, with the stock remaining entrenched in a downtrend despite a new regulatory submission in Brazil, underscores the prevailing risk of further declines, making the $8.22 support level a critical threshold for downside monitoring.